Considering the heterogeneity of breast cancer, the test dataset was further categorized by ER, PR, and HER2 status (positive or negative) into four subtypes: ER+, PR+, HER2+, and triple-negative breast cancer (TNBC). This evidence concerns the gene PGR and triple-negative breast carcinoma.